Method for the treatment of depression

- Janssen Pharmaceutica NV

The present invention is directed to method for the treatment of depression, for example, treatment resistant depression; wherein the treatment regimen is adjusted depending on the patient's genotype at SNP rs4306882.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Application 62/036,896, filed Aug. 13, 2014, the disclosure of which is herein incorporated by reference in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Aug. 11, 2015, is named “PRD3345USNP_SeqListing.txt” and is 56 kilobytes in size.

FIELD OF THE INVENTION

The present invention is directed to method for the treatment of depression, for example, treatment resistant depression; wherein the treatment regimen is adjusted depending on the patient's genotype at SNP rs4306882.

BACKGROUND OF THE INVENTION

Major Depressive Disorder is defined as the presence of one of more major depressive episodes that are not better accounted for psychotic disorder or bipolar disorder. A major depressive episode is characterized by meeting five or more of the following criteria during the same 2 week period which represent a change in functioning and include at least depressed/sad mood or loss of interest and pleasure, indifference or apathy, or irritability and is usually associated with a change in a number of neurovegetative functions, including sleep patterns, appetite and body weight, motor agitation or retardation, fatigue, impairment in concentration and decision making, feelings of shame or guilt, and thoughts of death or dying (Harrison's Principles of Internal Medicine, 2000). Symptoms of a depressive episode include depressed mood; markedly diminished interest or pleasure in all, or almost all, activities most of the day; weight loss when not dieting or weight gain, or decrease or increase in appetite nearly every day; insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt nearly every day; diminished ability to think or concentrate, or indecisiveness, nearly every day; recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide. Further, the symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, American Psychiatric Association, 1994)

Current treatment options for unipolar depression include monotherapy or combination therapy with various classes of drugs including mono-amine oxidase inhibitors (MAOI), tricyclic antidepressants (TCA), serotonin specific reuptake inhibitors (SSRI), serotonin noradrenergic reuptake inhibitors (SNRI), noradrenaline reuptake inhibitor (NRI), “natural products” (such as Kava-Kava, St. John's Wort), dietary supplement (such as s-adenosylmethionine) and others. More specifically, drugs used in the treatment of depression include, but are not limited to imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, maprotiline, amoxapine, trazodone, bupropion, chlomipramine, fluoxetine, citalopram, sertraline, paroxetine, tianeptine, nefazadone, venlafaxine, desvenlafaxine, duloxetine, reboxetine, mirtazapine, phenelzine, tranylcypromine, and/or moclobemide. Several of these agents including, but not limited to, serotonin reuptake inhibitors are also used when depression and anxiety co-exist, such as in anxious depression.

In the clinic, 40-50% of depressed patients who are initially prescribed antidepressant therapy do not experience a timely remission of depression symptoms. This group typifies level 1 treatment-resistant depression, that is, a failure to demonstrate an “adequate” response to an “adequate” treatment trial (that is, sufficient intensity of treatment for sufficient duration). Moreover, about approximately 30% of depressed patients remain partially or totally treatment-resistant to at least two antidepressant treatments including combination treatments. Increasingly, treatment of treatment-resistant depression includes augmentation strategies including treatment with pharmacological agents such as, antipsychotics (such as quetiapine, aripiprazole, olanzapine, risperidone, and the like), lithium, carbamazepine, and triiodothyronine, and the like; adjunctive electroconvulsive therapy; adjunctive transcranial magnetic stimulation; etc.

Suicide, also known as completed suicide, is the “act of taking one's own life”. Attempted suicide or non-fatal suicidal behavior is self-injury with the desire to end one's life that does not result in death. Suicidal ideations are thoughts of ending one's life but not taking any active efforts to do so.

Suicidal ideation is the medical term for thoughts about or an unusual preoccupation with suicide. The range of suicidal ideation varies greatly from fleeting to detailed planning, role playing, and unsuccessful attempts, which may be deliberately constructed to fail or be discovered, or may be fully intended to result in death. Although most people who undergo suicidal ideation do not go on to make suicide attempts, a significant proportion do. Suicidal ideation is generally associated with depression; however, it seems to have associations with many other psychiatric disorders, life events, and family events, all of which may increase the risk of suicidal ideation.

Suicidal ideation—may include, for example, suicidal thoughts—but may also include other related signs and symptoms. Some symptoms or co-morbid conditions may include unintentional weight loss, feeling helpless, feeling alone, excessive fatigue, low self-esteem, presence of consistent mania, excessively talkative, intent on previously dormant goals, feel like one's mind is racing. The onset of symptoms like these with an inability to get rid of or cope with their effects, a possible form of psychological inflexibility, is one possible trait associated with suicidal ideation. They may also cause psychological distress, which is another symptom associated with suicidal ideation. Symptoms like these related with psychological inflexibility, recurring patterns, or psychological distress may in some cases lead to the onset of suicidal ideation. Other possible symptoms and warning signs include: hopelessness, anhedonia, insomia, depression, severe anxiety, angst, impaired concentration, psychomotor agitation, panic attack and severe remorse.

Scales used in the evaluation of suicidal ideation include Beck Scale for Suicide Ideation (BSS), Columbia Suicide Severity Rating Scale and The Kessler Psychological Distress Scale (K10, which test does not measure suicidal ideation directly, but there may be value in its administration as an early identifier of suicidal ideation. High scores of psychological distress are also, in some cases associated with suicidal ideation.

There are also several psychiatric disorders that appear to be comorbid with suicidal ideation or considerably increase the risk of suicidal ideation. The following disorders have been shown to be the strongest predictors of suicidal ideation/disorders in which risk is increased to the greatest extent: major depressive disorder (MDD), dysthymia, bipolar disorder, post traumatic stress disorder (PTSD), personality disorders, psychosis (anxiety or detachment from reality), paranoia, schizophrenia and drug abuse.

The main treatments for suicidality and/or suicidal ideation include: hospitalization, outpatient treatment, and medication. Hospitalization allows the patient to be in a secure, supervised environment to prevent their suicidal ideation from turning into suicide attempts. In most cases, individuals have the freedom to choose which treatment they see fit for themselves. However, there are several circumstances in which individuals can be hospitalized involuntarily, including circumstances where an individual poses danger to self or others and where an individual is unable to care for one's self.

Outpatient treatment allows individuals to remain at their place of residence and receive treatment when needed or on a scheduled basis. Before allowing patients the freedom that comes with outpatient treatment, physicians evaluate several factors of the patient. These factors include the patient's level of social support, impulse control and quality of judgment. After the patient passes the evaluation, they are often asked to consent to a “no-harm contract”. This is a contract formulated by the physician and the family of the patient. Within the contract, the patient agrees not to harm themselves, to continue their visits with the physician, and to contact the physician in times of need. These patients are then checked on routinely to assure they are maintaining their contract and staying out of troublesome activities.

There are also a number of different pharmacological treatment options for those experiencing suicidal ideation. However, prescribing medication to treat suicidal ideation can be difficult. One reason for this is because many medications lift patients' energy levels before lifting their mood. This puts them at greater risk of following through with attempting suicide. Additionally, if a patient has a co-morbid psychiatric disorder, it may be difficult to find a medication that addresses both the psychiatric disorder and suicidal ideation. Therefore, the medication prescribed to one suicidal ideation patient may be completely different than the medication prescribed to another patient. However, there are several medications that seem to work fairly well for treating suicidal ideation, more particularly antidepressants, including fluoxetine (PROZAC), sertraline (ZOLOFT), paroxetine (PAXIL), fluvoxamine (LUVOX), venlafaxine (EFFEXOR) and nefazodone (SERZONE).

Although research is largely in favor of the use of antidepressants for the treatment of suicidal ideation, in some cases antidepressants are claimed to be associated with increased suicidal ideation. Upon the start of using antidepressants, many clinicians will note that sometimes the sudden onset of suicidal ideation may accompany treatment. This has caused the Food and Drug Administration (FDA) to issue a warning stating that sometimes the use of antidepressants may actually increase the thoughts of suicidal ideation.

Ketamine (a racemic mixture of the corresponding S- and R-enantiomers) is an NMDA receptor antagonist, with a wide range of effects in humans, including analgesia, anesthesia, hallucinations, dissociative effects, elevated blood pressure and bronchodilation. Ketamine is primarily used for the induction and maintenance of general anesthesia. Other uses include sedation in intensive care, analgesia (particularly in emergency medicine and treatment of bronchospasms. Ketamine has also been shown to be efficacious in the treatment of depression (particularly in those who have not responded to other anti-depressant treatment). In patients with major depressive disorders, ketamine has additionally been shown to produce a rapid antidepressant effect, acting within two hours.

The S-ketamine enantiomer (or S-(+)-ketamine or esketamine) has higher potency or affinity for the NMDA reception and thus potentially allowing for lower dosages; and is available for medical use under the brand name KETANEST S.

There remains a need to provide an effective treatment for depression, more particularly treatment resistant depression and/or for the treatment of suicidality, suicidal ideations, and for the prevention of suicide, particularly in the first hours and days after the onset of a major depressive episode.

SUMMARY OF THE INVENTION

The present invention is directed to a method for predicting whether a patient suffering from depression, preferably treatment resistant depression, is genetically predisposed to poorly respond to antidepressants, for example antidepressants which block the reuptake of monoamine neurotransmitters such as serotonin, norepinephrine, dopamine, and the like, comprising genotyping of said patient to determine the patient's genotype at SNP rs4306882 (on chromosome 3).

The present invention is further directed to a method for genotyping a patient to determine the patient's polymorphism at SNP rs4306882, comprising the steps of:

    • Step A: obtaining a biological sample comprising genetic material of the subject, wherein the subject is undergoing or is to undergo antidepressant pharmacotherapy;
    • Step B: determining the presence of a G ot T allele at rs4306882.

In an embodiment, the present invention is directed to a method for genotyping further comprising extracting DNA from the biological sample. In an embodiment, the present invention is directed to a method for genotyping wherein the biological sample is a blood sample. In an embodiment, the present invention is directed to a method for genotyping further comprising reporting the determination to the subject, a health care provider, a physician, a pharmacist, a pharmacy benefits manager or an electronic system.

The present invention is directed to a method for the treatment of depression, preferably treatment resistant depression (TRD), comprising:

    • Step A: genetically testing (or genotyping) a patient suffering from depression (preferably treatment resistant depression) to determine the patient's genotype at SNP rs4306882;
    • Step B: administering a dosing regimen of ketamine or esketamine, wherein the dosing regimen is adjusted to provide a higher dose and/or greater frequency of the ketamine or esketamine to those patients with a G allele (rather than a T allele) at the polymorphic site of SNP rs4306882.

In an embodiment of the present invention, the methods further comprise genetically testing (or genotyping) the patient suffering from depression, preferably treatment resistant depression, to determine the patient's genotype at one or more of the SNPs as listed in Table 3 which follows herein.

In an embodiment of the present invention, the patient suffering from depression, or in need of treatment for depression, is suffering from treatment resistant depression (TRD).

In an embodiment of the present invention, the dosing regimen comprises administration of esketamine, preferably intranasal esketamine. In an embodiment of the present invention, the esketamine is administered at a therapeutically effective amount. In another embodiment, the esketamine is administered as co-therapy in combination with one or more anti-depressants. In another embodiment of the present invention, the co-therapy is administered in a therapeutically effective amount.

In an embodiment of the present invention, wherein the patient in need of treatment is a patient carrying the G allele at SNP rs4306882, the dosing regimen comprises administration of intranasal esketamine at a dose of between about 28 mg and about 32 mg (preferably 28 mg), at an interval of one to four (preferably one to three, more preferably one to two, more preferably one) times per week, for a period of up to about eight weeks.

In another embodiment of the present invention, wherein the patient in need of treatment is a patient carrying the T allele at SNP rs4306882, the dosing regimen comprises administration of intranasal esketamine at a dose of between about 28 mg and about 32 mg (preferably 32 mg), at an interval of two to five (preferably three to five, more preferably four to five) times per week, for a period of up to about eight weeks.

In an embodiment of the present invention, the dosing regimen is administered for one to eight weeks, preferably for one to six weeks. In another embodiment of the present invention, the dosing regimen is administered for two to eight weeks, preferably for two to six weeks, preferably two to four weeks. In additional embodiments of the present invention, the dosing regimen is administered for one, two, three, four, five, six, seven or eight weeks.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to methods for the treatment of depression, more particularly treatment resistant depression, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations) comprising genotyping a patient in need thereof (e.g. suffering from depression, preferably treatment resistant depression) and administering ketamine, preferably esketamine, preferably intranasally, according to a dosing regimen which is selected (preferably optimized) for said patient, based on the patient's genotype at SNP rs4306882, alone or in combination with one or more SNPs, as described in more detail herein.

As used herein, unless otherwise noted, the term “esketamine” shall mean the (S)-enantiomer of ketamine, as its corresponding hydrochloride salt, a compound of formula (I)


also known as (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride.

As used herein, unless otherwise noted, the term “antidepressant” shall mean any pharmaceutical agent which can be used to treat depression. Suitable examples include, but are not limited to mono-amine oxidase inhibitors such as phenelzine, tranylcypromine, moclobemide, and the like; tricyclics such as imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, chlomipramine, amoxapine, and the like; tetracyclics such as maprotiline, and the like; non-cyclics such as nomifensine, and the like; triazolopyridines such as trazodone, and the like; serotonin reuptake inhibitors such as fluoxetine, sertraline, paroxetine, citalopram, citolapram, escitolapram, fluvoxamine, and the like; serotonin receptor antagonists such as nefazadone, and the like; serotonin noradrenergic reuptake inhibitors such as venlafaxine, milnacipran, desvenlafaxine, duloxetine and the like; noradrenergic and specific serotonergic agents such as mirtazapine, and the like; noradrenaline reuptake inhibitors such as reboxetine, edivoxetine and the like; atypical antidepressants such as bupropion, and the like; natural products such as Kava-Kava, St. John's Wort, and the like; dietary supplements such as s-adenosylmethionine, and the like; and neuropeptides such as thyrotropin-releasing hormone and the like; compounds targeting neuropeptide receptors such as neurokinin receptor antagonists and the like; and hormones such as triiodothyronine, and the like. Preferably, the antidepressant is selected from the group consisting of fluoxetine, imipramine, bupropion, venlafaxine and sertaline.

Therapeutically effective dosage levels and dosage regimens for antidepressants (for example, mono-amine oxidase inhibitors, tricyclics, serotonin reuptake inhibitors, serotonin noradrenergic reuptake inhibitors, noradrenergic and specific serotonergic agents, noradrenaline reuptake inhibitor, natural products, dietary supplements, neuropeptides, compounds targeting neuropeptide receptors, hormones and other pharmaceutical agents disclosed herein), may be readily determined by one of ordinary skill in the art. For example, therapeutic dosage amounts and regimens for pharmaceutical agents approved for sale are publicly available, for example as listed on packaging labels, in standard dosage guidelines, in standard dosage references such as the Physician's Desk Reference (Medical Economics Company or online at http://www.pdrel.com) or other sources.

As used herein the term “antipsychotic” includes, but is not limited to:

(a) typical or traditional antipsychotics, such as phenothiazines (e.g., chlorpromazine, thioridazine, fluphenazine, perphenazine, trifluoperazine, levomepromazin), thioxanthenes (e.g., thiothixene, flupentixol), butyrophenones (e.g., haloperidol), dibenzoxazepines (e.g., loxapine), dihydroindolones (e.g., molindone), substituted benzamides (e.g., sulpride, amisulpride), and the like; and

(b) atypical antipsychotics, such as paliperidone, clozapine, risperidone, olanzapine, quetiapine, zotepine, ziprasidone, iloperidone, perospirone, blonanserin, sertindole, ORG-5222 (Organon), and the like; and others such as sonepiprazole, aripiprazole, nemonapride, SR-31742 (Sanofi), CX-516 (Cortex), SC-111 (Scotia), NE-100 (Taisho), and the like.

In an embodiment, the “atypical antipsychotic” is selected from the group consisting of aripiprazole, quetiapine, olanzapine, risperidone and paliperidone. In another embodiment, the atypical antipsychotic is selected from the group consisting of aripiprazole, quetiapine, olanzapine and risperidone; preferably, the atypical antipsychotic is selected from the group consisting of aripiprazole, quetiapine and olanzapine.

As used herein, the term “depression” shall be defined to include major depressive disorder, unipolar depression, treatment resistant depression, depression with anxious distress, bipolar depression and dysthymia (also referred to as dysthymic disorder). Preferably, the depression is major depressive disorder, unipolar depression, treatment resistant depression, depression with anxious distress, or bipolar depression. More preferably, the depression is major depressive disorder, unipolar depression, treatment resistant depression and bipolar depression.

As used herein, the term “treatment-refractory or treatment-resistant depression” and the abbreviation “TRD” shall be defined as major depressive disorder that does not respond to adequate courses of at least two antidepressants. One skilled in the art will recognize that the failure to respond to an adequate course of a given antidepressant may be determined retrospectively or prospectively. In an embodiment, at least one of the failures to respond to an adequate course of antidepressant is determined prospectively. In another embodiment, at least two of the failures to respond to an adequate course of antidepressant are determined prospectively. In another embodiment, at least one of the failures to respond to an adequate course of antidepressant is determined retrospectively. In another embodiment, at least two of the failures to respond to an adequate course of antidepressant are determined retrospectively.

As used herein, unless otherwise noted, the terms “treating”, “treatment” and the like, shall include the management and care of a subject or patient (preferably mammal, more preferably human) for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or complications, alleviate the symptoms or complications, or eliminate the disease, condition, or disorder.

As used herein, unless otherwise noted, the term “prevention” shall include (a) reduction in the frequency of one or more symptoms; (b) reduction in the severity of one or more symptoms; (c) the delay or avoidance of the development of additional symptoms; and/or (d) delay or avoidance of the development of the disorder or condition.

One skilled in the art will recognize that wherein the present invention is directed to methods of prevention, a subject in need of thereof (i.e. a subject in need of prevention) shall include any subject or patient (preferably a mammal, more preferably a human) who has experienced or exhibited at least one symptom of the disorder, disease or condition to be prevented. Further, a subject in need thereof may additionally be a subject (preferably a mammal, more preferably a human) who has not exhibited any symptoms of the disorder, disease or condition to be prevented, but who has been deemed by a physician, clinician or other medical profession to be at risk of developing said disorder, disease or condition. For example, the subject may be deemed at risk of developing a disorder, disease or condition (and therefore in need of prevention or preventive treatment) as a consequence of the subject's medical history, including, but not limited to, family history, pre-disposition, co-existing (comorbid) disorders or conditions, genetic testing, and the like.

As used herein, unless otherwise noted, the terms “subject” and “patient” refer to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment. Preferably, the subject or patient has experienced and/or exhibited at least one symptom of the disease or disorder to be treated and/or prevented.

The term “therapeutically effective amount” as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

Wherein the present invention is directed to therapy with a combination of agents, “therapeutically effective amount” shall mean that amount of the combination of agents taken together so that the combined effect elicits the desired biological or medicinal response. For example, the therapeutically effective amount of combination therapy comprising esketamine and a serotonin reuptake inhibitor would be the amount of esketamine and the amount of the serotonin reuptake inhibitor that when taken together or sequentially have a combined effect that is therapeutically effective, more preferably where the combined effect is synergistic. Further, it will be recognized by one skilled in the art that in the case of combination therapy with a therapeutically effect amount, the amount of each component of the combination individually may or may not be therapeutically effective.

Wherein the present invention is directed to the administration of a combination, the compounds may be co-administered simultaneously, sequentially, separately or in a single pharmaceutical composition. Where the compounds are administered separately, the number of dosages of each compound given per day, may not necessarily be the same, e.g. where one compound may have a greater duration of activity, and will therefore, be administered less frequently. Further, the compounds may be administered via the same or different routes of administration, and at the same or different times during the course of the therapy, concurrently in divided or single combination forms. The instant invention is therefore understood as embracing all regimens of simultaneous or alternating treatment and the term “administering” is to be interpreted accordingly.

As used herein, the terms “co-therapy”, “combination therapy”, “adjunctive treatment”, “adjunctive therapy” and “combined treatment” shall mean treatment of a patient in need thereof by administering esketamine in combination with one or more antidepressant(s), and further, optionally in combination with one or more atypical antipsychotics wherein the esketamine and the antidepressant(s) are administered by any suitable means, simultaneously, sequentially, separately or in a single pharmaceutical formulation. Where the esketamine and the antidepressant(s) are administered in separate dosage forms, the number of dosages administered per day for each compound may be the same or different. The esketamine and the antidepressant(s) may be administered via the same or different routes of administration. Examples of suitable methods of administration include, but are not limited to, oral, intravenous (iv), intranasal (in) intramuscular (im), subcutaneous (sc), transdermal, and rectal. Compounds may also be administered directly to the nervous system including, but not limited to, intracerebral, intraventricular, intracerebroventricular, intrathecal, intracisternal, intraspinal and/or peri-spinal routes of administration by delivery via intracranial or intravertebral needles and/or catheters with or without pump devices. The esketamine and the antidepressant(s) may be administered according to simultaneous or alternating regimens, at the same or different times during the course of the therapy, concurrently in divided or single forms.

Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound or compounds used, the mode of administration, the strength of the preparation and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient's sex, age, weight, diet, time of administration and concomitant diseases, will result in the need to adjust dosages.

One skilled in the art will recognize that, both in vivo and in vitro trials using suitable, known and generally accepted cell and/or animal models are predictive of the ability of a test compound to treat or prevent a given disorder.

One skilled in the art will further recognize that human clinical trials including first-in-human, dose ranging and efficacy trials, in healthy patients and/or those suffering from a given disorder, may be completed according to methods well known in the clinical and medical arts.

As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term “about”. It is understood that whether the term “about” is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including approximations due to the experimental and/or measurement conditions for such given value.

To provide a more concise description, some of the quantitative expressions herein are recited as a range from about amount X to about amount Y. It is understood that wherein a range is recited, the range is not limited to the recited upper and lower bounds, but rather includes the full range from about amount X through about amount Y, or any amount or range therein.

For use in medicine, the salts of the compounds of this invention refer to non-toxic “pharmaceutically acceptable salts.” Other salts may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts. Thus, representative pharmaceutically acceptable salts include, but are not limited to, the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate.

Representative acids which may be used in the preparation of pharmaceutically acceptable salts include, but are not limited to, the following: acids including acetic acid, 2,2-dichloroacetic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucoronic acid, L-glutamic acid, α-oxo-glutaric acid, glycolic acid, hipuric acid, hydrobromic acid, hydrochloric acid, (+)-L-lactic acid, (±)-DL-lactic acid, lactobionic acid, maleic acid, (−)-L-malic acid, malonic acid, (±)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinc acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebaic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid and undecylenic acid.

Representative bases which may be used in the preparation of pharmaceutically acceptable salts include, but are not limited to, the following: bases including ammonia, L-arginine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylenediamine, N-methyl-glucamine, hydrabamine, 1H-imidazole, L-lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, 1-(2-hydroxyethyl)-pyrrolidine, secondary amine, sodium hydroxide, triethanolamine, tromethamine and zinc hydroxide.

EXAMPLES

The following Examples are set forth to aid in the understanding of the invention, and are not intended and should not be construed to limit in any way the invention set forth in the claims which follow thereafter.

Example 1—Retrospective Analysis

We performed a genetic association meta-analysis of treatment resistant depression case control genetic association analyses from two independent cohorts of European ancestry. Irrespective of the definition provided above, in the meta-analysis described in this Example, cases with treatment resistant depression (TRD) were defined as subjects failing two trials of antidepressant treatment regimens and were drawn either from a Cohort J consisting of patients enrolling in antidepressant clinical studies (n=232) genotyped using Ilumina Omni5MExome or from a cohort based on STAR*D study (n=315) genotyped using either Affymetrix 500K or Affymetrix 5.0. Controls were drawn from either the cognitively normal subjects from the ADNI study (n=255) genotyped using Illumina Omni2.5M or the psychiatrically screened healthy controls from NIMH (n=584) genotyped using Affymetrix 500K, respectively. We imputed genotypes based on the reference haplotypes from the 1,000 Genomes prior to meta-analysis to enable direct comparison of variants across the study.

More specifically, for Cohort J, we started with the Illumina Omni5MExome dataset (n˜538) comprising subjects from the following studies: (a) RIS-INT-93 (˜458 Caucasian subjects including 24 Hispanic subjects); (b) ESKETIV-TRD-2001 (n˜26, all races); (c) KETIV-TRD-2002 (n˜61, all races). Only the patients meeting TRD criteria were defined as cases and only subjects of European ancestry were included in the analysis leading to this invention. Standard SNP-level and subject-level quality control criteria were applied prior to imputation of sites not directly genotyped. SNP-level quality control criteria included 1) Minor Allele Frequency >1%; 2) SNP-wise genotype missing rate <5%; 3) Hardy-Weinberg Equilibrium p-value >1e-06. Subject-level quality control criteria included 1) subject-wise genotype missing rate <5%; 2) excluded population outliers, cryptic related subject, and subjects with genetically derived gender differing from gender captured in the case report form (CRF) or phenotype file (if exists). The controls for Cohort J were ADNI CN (genotyped using Illumina Omni2.5M, n˜281). For the 2nd cohort, the Affymetrix 500K Mapping Array/Affymterix 5.0 comprised the STAR*D (n˜1851 all races) and NIMH controls (n˜1727 all races). Similar case definition criteria and similar quality control criteria were applied. The 2 analysis cohorts matched by genotyping platforms were: 1) Cohort J TRD (Omni2.5M using a subset of markers) vs. ADNI CN (Omni2.5M) and 2) STAR*D TRD vs. NIMH controls screened by Composite International Diagnostic Interview (CIDI-SF) self-report modified to screen for lifetime diagnoses (The Internet-Based MGS-2 Control Samples).

Treatment resistant depression (TRD) was defined as follows: 2 antidepressant failures (1 retrospective and 1 prospective failure for RIS-INT-93; 2 prospective antidepressant failures for STAR*D; or 2 retrospective antidepressant failures for ESKETIV-TRD-2001 & KETIV-TRD-2002). Prospective antidepressant failure was defined by using HAM-D-17 clinical scale for patients with percentage of change in HAM-D-17 score greater than −50%. The minimal treatment length was 6 weeks for RIS-INT-93 and 8-12 weeks for STAR*D.

The associated markers in the meta-analysis (directly genotyped marker P=8.51×10−7; imputed marker P=3.56×10−8 passing the conventional genome-wide significance threshold (P=5×10−8)) were located in a 50 kb interval (3p24.3) in chromosome 3 with only unannotated spliced EST reported, within a linkage interval implicated in a linkage meta-analysis (3p25.3-3p22.1). The genetic data from each TRD sample independently supported this association, with uncorrected significance levels of P=2.37×10−5 for the STAR*D cohort and P=0.005 for the Cohort J. (See Table 1 and Table 2, below). Minor allele G was determined to occur at a lower frequency in TRD than in a generally healthy population. Patients with each copy of the G allele had ˜0.7× lower odds of exhibiting treatment resistant depression (TRD). rs4306882 was directly genotyped in Cohort J; and imputed in the STAR*D cohort.

TABLE 1 Cohort CHR SNP BP A1 A2 Cohort J vs. 3 rs 4306882 21062584 G T ADNI CN STAR*D TRD 3 rs 4306882 21062584 G T vs. NIMH Controls Cohort FRQ INFO OR SE P Cohort J vs. 0.386 0.9777 0.6754 0.14 0.005078 ADNI CN STAR*D TRD 0.3771 1.0139 0.5249 0.1525 2.37E−05 vs. NIMH Controls

Abbreviations in Table 1 are as follows:
    • CHR Chromosome code, if map file specified
    • SNP SNP code
    • BP Base-pair position, if map file specified
    • A1 Allele 1 code
    • A2 Allele 2 code
    • FRQ Frequency of A1, from dosage data
    • INFO R-squared quality metric/information content
    • OR Odds ratio for association
    • SE Standard error of effect estimate
    • P p-value for association tests

TABLE 2 For Chromosome 3, SNP rs4306882 at Base pair position 21062587 A1 F A F U A2 CHISQ P OR G 0.3378 0.4321 T 10.16 1.43E−03 0.6703

Abbreviations in Table 2 are as follows:
    • A1 Minor allele name (based on whole sample)
    • F_A Frequency of this allele in cases
    • F_U Frequency of this allele in controls
    • A2 Major allele name
    • CHISQ Basic allelic test chi-square (1df)
    • P Asymptotic p-value for this test
    • OR Estimated odds ratio (for A1, i.e. A2 is reference)

The sequence ID for SNP rs4306882 is as follows:

SEQ. ID. 1: GGATGCCACA TGCAGATGTA TTTTCTTTGG TCCACATATG GCATCCAACC CATGAGCTAT AGAAAATATG GATTTCTGGA TTTCTTTGAA ACACTGAAAG ATCTGGAGCC TCTGGGCCAC TGTTACTGGA TAATAGCAAC AGCCTGAGTG TTTGCATTTA TAACCTGTAA TAAGAGACGC ATGTCTCCTT GCTGCTCAAG TTATAGATCT GACAGCCCAG GATATGATTA ATCAGAGCTC AGGGCTCAGG AAGCCATTCT CCACATCTGG CAGAGCCCGA CAAAATCTTT GCAATCAGAT TAACGAAGCA GTGACATGAT GTTCTATTAG TGGGGGCATG GACATGCAAA ATCATTATGC AGAACAATTC ATTATCATAG CTGACCATGT ACAGGGTTTT AGCTGCATGT CGATGTGGCA CAGCTCACTG AAGATGCATG GATAAACGCT GTGGCTAAGG CATTGTGAGA GCAATTGGTA GGAGCTAGAA AGCTAGCTCT K AAGCCAAGCT AGAAGAGAAA CACAGTTCTG GGATCACCAT TCATTTTGCT CTTTCTGGGT CCTTTTATAT CTGCTTTAGC AAGGTACCTG CTTTAACAAT GTACATTCTT GCATGAATGT TTTCTTTTCT CTTTCAATTC TTCTTCCATC CTGGTGTTTA GGATATCACT GGGGTGGGAT AGTGGGAGAG GTGGCAGTTT TATTTTGTTT TTAAGTATAT CAGTTCTCCT TTTTGATATC AGCTTTTCTT TTTGAATAGT CCAGGATATA CTTGCCTCTC AAGCAGCTTT TTTTTTTCTC AAAGCCAGTT CTTCTTATGC AACAGACTTA CTATATCATT CACAGATTGT ACCATGAGGG TTCACTTTCT TGCACCTATA TTAGGCCACA ACCTCTAAGC ACAAAGGTCT TTTCATGACT GTTTATTGAA ATACCCAGCA AGAATTTTCA TCAGACAGAG TTTTAGTCAT GCTTTAACTC TGCAACTTAT TAAAATGGGA >gnl|dbSNP|rs4306882|allelePos = 501| totalLen = 1001|taxid = 9606|snpclass = 1| alleles = ‘G/T’|mol = Genomic|build = 138

SNP rs4306882 was further determined to be in linkage disequilibrium (LD) with an array of the SNPs in the close by genomics region as shown in Table 3, below.

In certain embodiments, the present invention is directed to methods (as described herein) wherein the patient's genotype is determined at any single SNP listed in Table 3 below, alone or in combination with a determination of the patient's genotype at SNP rs4306822. In certain embodiments, the present invention is directed to methods (as described herein) wherein the patient's genotype is determined at any subset of SNPs selected from the list in Table 3 below, alone or in combination with a determination of the patient's genotype at SNP rs4306822.

TABLE 3 BP SNP A1 A2 N P P(R) OR OR(R) Q I Chromosome 2 (CHR) 119536884 rs1551133 C A 2 2.85E−07 1.68E−04 0.4418 0.4392 0.1699 46.91 Chromosome 3 (CHR) 21061286 rs869495 G A 2 5.54E−07  0.0006712 0.5941 0.5898 0.1367 54.84 21061473 rs869494 T A 2 6.68E−07 0.001478  0.5967 0.5914 0.1129 60.21 21062584 rs4306882 G T 2 8.51E−07 4.85E−05 0.6019 0.5997 0.2233 32.57 21063058 rs4465961 T C 2 8.85E−07 0.000537  0.5939 0.5897 0.1513 51.43 21063578 rs7625772 T G 2 6.24E−07 0.00096   0.5947 0.5897 0.1263 57.21 21063804 rs7633632 G A 2 6.21E−07 5.14E−06 0.5963 0.5954 0.2733 16.68 21063919 rs7612422 C G 2 1.43E−07 1.64E−07 0.5804 0.5803 0.3149 1 21067747 rs7646153 G C 2 8.42E−07  0.0004885 0.5984 0.5947 0.1539 50.81 21069166 rs1391144 G A 2 9.95E−07 9.95E−07 0.6022 0.6022 0.3234 0 21072614 rs2047387 G A 2 2.04E−07 2.04E−07 0.5822 0.5822 0.3415 0 21077201 rs6769146 G A 2 4.83E−07 4.83E−07 0.5911 0.5911 0.3302 0 21077685 rs6550565 G C 2 7.97E−07 6.70E−06 0.5866 0.5856 0.272 17.12 21081507 rs56871503 C T 2 6.99E−07  0.0004664 0.5965 0.593 0.1525 51.14 21085039 rs11295121 TG T 2 9.11E−07 9.11E−07 0.6007 0.6007 0.3262 0 21087408 rs4858288 A G 2 3.76E−07 3.76E−07 0.5893 0.5893 0.3634 0 21088048 rs1391138 G T 2 2.82E−07 2.82E−07 0.5852 0.5852 0.3252 0 21088878 rs9881998 C T 2 5.63E−07 3.08E−05 0.5918 0.59 0.228 31.2 21089069 rs9811079 G A 2 2.62E−07 2.62E−07 0.5843 0.5843 0.3787 0 21093953 rs13097458 C A 2 9.97E−07 9.97E−07 0.597 0.597 0.389 0 21097393 rs973870 C A 2 6.85E−07  0.0004483 0.5957 0.5918 0.1531 51.01 21099489 rs7652147 G A 2 7.14E−07  0.0004306 0.5958 0.5921 0.1551 50.52 21099939 rs141786492 TTTTC T 2 4.54E−07  0.0008831 0.5822 0.5771 0.1245 57.63 21100108 rs7644744 A G 2 6.62E−07 0.000343  0.5943 0.5908 0.1612 49.05 21102620 rs985536 G A 2 6.54E−07 6.54E−07 0.5921 0.5921 0.4025 0 21106260 rs9865061 T A 2 2.28E−07 8.84E−05 0.58 0.5773 0.184 43.35 21106404 rs11128983 G A 2 5.11E−07 5.42E−05 0.589 0.5868 0.211 36.07 21107235 rs9850499 C T 2 3.45E−07 2.87E−05 0.5798 0.5779 0.221 33.23 21107330 rs71935600 CAG C 2 2.39E−07  0.0001414 0.5709 0.5676 0.1714 46.55 21108963 rs200621794 AAAG A 2 3.56E−08 3.56E−08 0.5581 0.5581 0.3527 0 21108964 rs67575809 AAG A 2 2.80E−08 2.51E−07 0.5549 0.5546 0.2812 13.9 21109078 rs7372757 G A 2 2.25E−07 2.25E−07 0.5801 0.5801 0.7251 0 Chromosome 4 (CHR) 148693230 rs2164527 C T 2 4.17E−07 4.17E−07 0.451 0.451 0.6757 0 Chromosome 11 (CHR) 86572384 rs12285365 G A 2 4.43E−07 4.43E−07 0.5116 0.5116 0.6906 0

Abbreviations in Table 3 above, are as follows:
    • CHR Chromosome code, if map file specified
    • BP Base-pair position, if map file specified
    • SNP SNP code
    • A1 Allele 1 code
    • A2 Allele 2 code
    • N Number of valid studies for the SNP
    • P p-value for association tests
    • P(R) Random-effectsmeta-analysis p-value
    • OR Odds ratio for association
    • OR(R) Random effects OR estimate
    • Q p-value for Cochrane's Q stratistic
    • I I2 heterogeneity index (0-100)

Thus, we believe that we have identified a candidate genetic marker for TRD with association p-value passing genome wide significance using a relatively small sample size by GWAS standard. The identification of genetic markers associated with resistance to biogenic amine-based antidepressant drugs holds the potential to guide researchers toward unprecedented targets in the discovery of novel treatments for TRD.

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

Claims

1. A method for treatment of depression comprising:

Step A) obtaining a biological sample comprising genetic material from a patient suffering from depression;
Step B) detecting the patients genotype at rs4306882 by performing a genotyping assay on the genetic material from Step A;
Step C) detecting a G allele at the polymorphic site of rs4306882 in the patients genetic material; and
Step D) administering esketamine intranasally at a dosage of about 28 mg to about 32 mg, one to three times per week for up to eight weeks to said patient.

2. The method as in claim 1, wherein the depression is treatment resistant depression (TRD).

3. The method of claim 2 wherein the patient with treatment resistant depression is administered esketamine in co-therapy in combination with a therapeutically effective amount of at least one antidepressant.

4. A method for treatment of depression comprising:

Step A) obtaining a biological sample comprising genetic material from a patient suffering from depression;
Step B) detecting the patients genotype at rs4306882 by performing a genotyping assay on the genetic material from Step A;
Step C) detecting a T allele at the polymorphic site of rs4306882 in the patients genetic material; and
Step D) administering esketamine intranasally at a dosage of about 28 mg to about 32 mg, four to five times per week for up to eight weeks to said patient.

5. The method of claim 4, wherein the depression is treatment resistant depression (TRD).

6. The method of claim 5, wherein the patient with treatment resistant depression is administered esketamine in co-therapy in combination with a therapeutically effective amount of at least one antidepressant.

Referenced Cited
U.S. Patent Documents
5543434 August 6, 1996 Weg
6040479 March 21, 2000 Steiner et al.
6176242 January 23, 2001 Rise
7273889 September 25, 2007 Mermelstein
7687080 March 30, 2010 Wolicki
7973043 July 5, 2011 Migaly
20040214215 October 28, 2004 Yu et al.
20060276550 December 7, 2006 Bhagwat
20070287753 December 13, 2007 Charney et al.
20090306137 December 10, 2009 Wolfgang et al.
20110112131 May 12, 2011 Holtman et al.
20110306674 December 15, 2011 Schiene et al.
20120225949 September 6, 2012 Papalos
20130172361 July 4, 2013 Fava et al.
20130236573 September 12, 2013 Singh et al.
20140093592 April 3, 2014 Jaskaran et al.
20140256821 September 11, 2014 Charney et al.
20160332962 November 17, 2016 Chen et al.
20160338977 November 24, 2016 Singh et al.
Foreign Patent Documents
2062620 July 1971 DE
4312016 October 1994 DE
19619665 November 1997 DE
102007009888 September 2008 DE
1103256 May 2001 EP
63002932 January 1988 JP
199423711 October 1994 WO
200004875 February 2000 WO
2007111880 October 2007 WO
2011020061 February 2011 WO
2014031975 February 2014 WO
2014169272 October 2014 WO
Other references
  • Tansey et al; Biol Psychiatry, vol. 73, 2013, pp. 679-682.
  • Diazgranados_et_al, Rapid Resolution of Suicidal ideation After a Single Infusion of an N-Methyl-D Aspartate Antagonist in Pateient With Treatment-Resistant Majar Depressive Disorder, J Clin Psychiatry, 2010, pp. 1605-1611, vol. 71 Issue 12, Physicians Postgraduate Press.
  • Gomes,et al., Neurotoxicity of Subarachnoid Preservative—Frees (+)-Ketamine in Dogs, Pain Physician, 2011, pp. 83-90, vol. 14.
  • Hijazi,et al., Stability of Ketamine and Its metabolites Norketamine and Dehydronorketamine in Human Biological Samples, Clinical Chemistry, 2001, pp. 1713-1715, vol. 47 Issue 9.
  • Ho,et al., In vitro effects of preservatives in nasal sprays on human nasal epithelial cells, American Journal of Rhinology, 2008, pp. 125-129, vol. 22.
  • Hong,et al., Allergy to ophthalmic preservatives, Current Opinion in Allergy and Clinical Immunology, 2009, pp. 447-453, vol. 9.
  • Huang,et al., Mechanism of nasal Absorption of Drugs I: Physicochemical Parameters Influencing the rate of In Situ Nasal Absorption of Drugs in Rats, Journal of Pharmaceutical Science, Feb. 27, 1985, pp. 608-611, vol. 74 Issue 6.
  • Huge,et al., Effects of low—dose intranasal (S)- ketamine in patients with neuropathic pai, European Journal of Pain, Sep. 3, 2009, pp. 387-394, vol. 14, Elsevier Ltd.
  • Johansson,et al., Prehospital analgesia using nasal administration of S-ketamine-a case series, Scandinavian Journal of Trauma, 2013, pp. 1-5, vol. 21 Issue 38, BioMed Central Ltd.
  • Logan,et al., Immobilizing Wild Mountain Lions ( Fells Concolor) with Ketamine hydrochloride and Xylazine Hydrochloride, Journal of Wildlife Diseases, 1986, pp. 97-103, vol. 22 Issue 1.
  • Marhofer, et al, S( +)-Ketamine for caudal block in paediatric anaesthesia, British Journal of Anaesthesia, 2000, pp. 341-345, vol. 84 Issue 3.
  • Mathew_et_al, Ketamine for Treatment-Resistant Unipolar Depression, CNS Drugs, 2012, pp. 189-204, vol. 26 Issue 3, Adis Data Information BV.
  • Noppers_et_al, Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: A randomized, prospective, double blind, active placebo-controlled trial, European Journal of Pain, Apr. 11, 2011, pp. 942-949, vol. 15, Elsevier Ltd.
  • Oishi,et al., Effects of propyl paraben on the male reproductive system, Food and Chemical Toxicology, Jul. 7, 2002, pp. 1807-1813, vol. 40, Elsevier Science Ltd.
  • Okamoto_et_al, Rapid Antidepressant Effect of Ketamine Anesthesia During Electroconvulsive Therapy of Treatment-Resistant Depression, Journal of ECT, 2010, pp. 223-227, vol. 26 Issue 3, Lippincott Williams & Wilkins.
  • Paslakis_et_al, Oral Administration of the NMDA Receptor Antagonist S-Ketamine as Add-On Therapy of Depression: A Case Series, Pharmacopsychiatry, 2010, pp. 33-35, vol. 43.
  • Paul_et_al, Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: Report of two cases, The World Journal of Biological Psychiatry Sep. 28, 2007, pp. 241-244, vol. 10 Issue 3, Informa UK Ltd.
  • Pfizer, (S)-(+)-Ketamine Hydrochloride Solution, Material Safety Data Sheet, Nov. 5, 2008, pp. 1-8, Version 1.0.
  • PRD3253CLPCT_Opposition Brief Translation, 2014.
  • Price_et_al, Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression, BIOL PSYCHIATRY, 2009, pp. 522-526, vol. 66, Society of Biological Psychiatry.
  • Sarchiapone, et al., Association of Polymorphism (Val66met) of Brain-Derived Neurotrophic Factor with Sucide Attempts in Depressed Patients, Neuropsychobiology, Jul. 7, 2008, pp. 139-145, vol. 57.
  • Skolnick_et_al, Glutamate-based antidepressants: 20 years on, Trends in Pharmacological Sciences, 2006, pp. 563-569, vol. 30 Issue 11.
  • Soni,et al., Safety assessment of esters of p-hydroxybenzoic acid (parabens, Food and Chemical Toxicology, Jan. 31, 2005, pp. 985-1015, vol. 43, Elsevier Ltd.
  • Soni,et al., Safety assessment of propyl paraben: a review of the published literature, Food and Chemical Toxicology, Sep. 25, 2000, pp. 513-532, vol. 39, Elsevier Science LTD.
  • Stevenson, Ketamine:A Review, Update in Anaesthesia, 2005, pp. 25-29, vol. 20.
  • Tansey et al., Contribution of Common Genetic Variants to Antidepressant Response, BIOL PSYCHIATRY, 2013, 679-682, 73.
  • Vranken_et_al, Iontophoretic administration of S(C)-ketamine in patients with intractable central pain: A placebo-controlled trial, Pain, Aug. 15, 2005, pp. 224-231, vol. 118, Elsevier B.V.
  • Washington,et al., Determination of baseline human nasal pH and the effect of intranasally administered buffers, International Journal of Pharmaceutics, Nov. 24, 1999, pp. 139-146, vol. 198, Elsevier Science B.V.
  • White _et_al, Pharmacology of Ketamine Isomers in surgical Patients, Anesthesiology, 1980, pp. 231-239, vol. 52, The American Society of Anesthesiologists.
  • White,et al., Comparative Pharmacology of ketamine Isomers, British Journal of Anaesthesia, 1985, pp. 197-203, vol. 57 Issue 2.
  • WIKIPEDIA, Esketamine, Wikipedia, Sep. 1, 2015, pp. 1-4, Wikipedia.
  • Clinical Trials.Gov _NCT01998958, A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression. ClinicaiTrials.gov Identifier: NCT01998958. Jul. 14, 2014 [online]. [Retrieved on Sep. 23, 2015]. Retrieved from the Internet: <URL: https://clinicaltrials.gov/archive/NCT01998958/2014_07 14> PDF FILE: p. 1-40. p. 1, Brief Summary, Phase, and the last para; and p. 2, para 1 and 3.
  • GENBANK_AC099753, Homo sapiens chromosome 3 clone RP11-466A13, complete sequence. Mar. 20, 2002, [online]. [Retrieved on Oct. 1, 2015]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/nuccore/19551144/> Pdf file: p. 1-40. p. 1, Definition; p. 3, Origin, p. 27, the nucleotide sequence between 113924-112924, especially the nucleotides between 113.444-113405; and the nucleotide at the position of 113424.
  • Gonzalo Laje et al: “Correspondence Brain-Derived Neurotrophic Factor Va166Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients”, BIOL PSYCHIATRY, vol. 72, No. 11, Dec. 1, 2012 (Dec. 1, 2012), pp. e27-e28.
  • Anonymous: “NCT02133001 on Jun. 23, 2014: ClinicalTrials.gov Archive”, Jun. 23, 2014 (Jun. 23, 2014), pp. 1-6, XP055230128, Retrieved from the Internet: URL:https://clinicaltrials.gov/archive/NCT 02133001/2014_06_23.
  • Salvadore G ED-Sanacora Gerard et al: “Impact of the Val66Met Polymorphism of Brain-Derived Neurotrophic Factor on Esketamine and Ketamine Antidepressant Effects in Patients with Treatment-Resistant Depression”, Biological Psychiatry, Elsevier Science, Newyork, NY; US, vol. 77, No. 9 supplement, May 1, 2015 (May 1, 2015), p. 360S.
  • International Search Report re: PCT/US2013/030476 dated Apr. 24, 2013.
  • International Search Report re: PCT/US2014/027059 dated Jul. 16, 2014.
  • International Search Report re: PCT/US2014/027074 dated May 27, 2014.
  • International Search Report re: PCT/US2015/44830 dated Nov. 23, 2015.
  • International Search Report re: PCT/US2015/049961 dated Jan. 12, 2016.
  • International Search Report re: PCT/EP2016/060922 dated Jul. 28, 2016.
  • International Search Report re: PCT/US2016/33404 dated Aug. 16, 2016.
Patent History
Patent number: 10098854
Type: Grant
Filed: Aug 12, 2015
Date of Patent: Oct 16, 2018
Patent Publication Number: 20160045455
Assignee: Janssen Pharmaceutica NV
Inventors: Wayne C. Drevets (Newton, PA), Qingqin S. Li (Flemington, NJ)
Primary Examiner: Jehanne S Sitton
Application Number: 14/824,513
Classifications
Current U.S. Class: Non/e
International Classification: C12Q 1/68 (20180101); A61K 31/135 (20060101); C12Q 1/6883 (20180101);